MD871Z - Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer - Google Patents
Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer Download PDFInfo
- Publication number
- MD871Z MD871Z MDS20140054A MDS20140054A MD871Z MD 871 Z MD871 Z MD 871Z MD S20140054 A MDS20140054 A MD S20140054A MD S20140054 A MDS20140054 A MD S20140054A MD 871 Z MD871 Z MD 871Z
- Authority
- MD
- Moldova
- Prior art keywords
- breast cancer
- radiotherapy
- patients
- chemotherapy
- complications
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 32
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 32
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 18
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002113 nanodiamond Substances 0.000 claims abstract description 16
- 235000012054 meals Nutrition 0.000 claims abstract description 11
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 10
- 239000010476 amaranth oil Substances 0.000 claims abstract description 9
- 239000004359 castor oil Substances 0.000 claims abstract description 9
- 235000019438 castor oil Nutrition 0.000 claims abstract description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 9
- 240000001592 Amaranthus caudatus Species 0.000 claims abstract description 8
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims abstract description 8
- 235000012735 amaranth Nutrition 0.000 claims abstract description 8
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 238000001802 infusion Methods 0.000 claims description 8
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 6
- 240000000785 Tagetes erecta Species 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract 1
- 235000003880 Calendula Nutrition 0.000 abstract 1
- 240000001432 Calendula officinalis Species 0.000 abstract 1
- 229940098465 tincture Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 12
- 241000245665 Taraxacum Species 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000736851 Tagetes Species 0.000 description 3
- 235000012308 Tagetes Nutrition 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 206010001233 Adenoma benign Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000035346 Margins of Excision Diseases 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000033206 Early menarche Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000009923 canephron Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la oncologie, şi poate fi utilizată pentru profilaxia complicaţiilor radioterapiei sau chimioterapiei la pacienţii cu cancer al glandei mamare. The invention relates to medicine, in particular to oncology, and can be used for the prophylaxis of complications of radiotherapy or chemotherapy in patients with breast cancer.
Cancerul glandei mamare este cea mai frecventă malignitate la femei, mai ales în ţările europene, fiind cea mai frecventă cauză de deces prin cancer la femei. Breast cancer is the most common malignancy in women, especially in European countries, and is the most common cause of cancer death in women.
Informarea sanitară a populaţiei feminine determină femeia să se prezinte la medic mai timpuriu dacă observă un semn clinic la nivelul sânilor. Health information for the female population encourages women to see a doctor earlier if they notice a clinical sign in their breasts.
Primele referiri la cancerul mamar apar în papirusul denumit ,,Chirurgical a lui Edwin Smith” scris între anii 2500…3000 i.e.n., iar primul moment terapeutic este atribuit lui Gallen, care recomandă excizia tumorii incipiente. The first references to breast cancer appear in the papyrus called "Chirurgical of Edwin Smith" written between 2500…3000 BC, and the first therapeutic moment is attributed to Gallen, who recommends excision of the incipient tumor.
Un moment important în evoluţia tratamentului îl constituie introducerea mastectomiei radicale de către W.S. Halsted în 1882 şi Willy Meyer în 1894. An important moment in the evolution of treatment was the introduction of radical mastectomy by W.S. Halsted in 1882 and Willy Meyer in 1894.
Noţiunea de cancer mamar operabil trebuie abordată şi prin prisma clasificării T.N.M. The notion of operable breast cancer must also be approached through the lens of the T.N.M. classification.
Din punct de vedere strict al tehnicii chirurgicale, orice cancer mamar este operabil, cu excepţia celor care au tumoarea invadată în peretele toracic şi/sau metastaze ganglionare invadate în structurile vasculonervoase ale axilei. From a strict surgical technique point of view, any breast cancer is operable, except for those with tumor invasion into the chest wall and/or lymph node metastases invaded into the neurovascular structures of the axilla.
Cancerul glandei mamare este o problemă majoră de sănătate publică ce priveşte întreg mapamondul. În cea mai mare parte a Europei, în America de Nord, Australia şi Noua Zeelandă cancerul mamar este cel mai frecvent întâlnit la femei şi, de asemenea, reprezintă cea mai frecventă cauză de deces la femeile cu vârsta cuprinsa între 35 şi 54 ani. Incidenţa cancerului mamar este în creştere în întreaga lume din cauze incomplet elucidate. S-a raportat o creştere de 3% pe an a frecvenţei cancerului mamar. Aceasta se datorează pe de o parte creşterii numărului de programe screening, care permit detectarea în stadii incipiente, iar pe de altă parte îmbătrânirii populaţiei. Rata mortalităţii a rămas în general neschimbată în ultimii 50 ani în pofida îmbunătăţirii tratamentului şi a depistării în stadii incipiente. Breast cancer is a major public health problem worldwide. In most of Europe, North America, Australia and New Zealand, breast cancer is the most common cancer in women and is also the most common cause of death in women aged 35 to 54 years. The incidence of breast cancer is increasing worldwide for reasons that are not fully understood. A 3% increase per year in the frequency of breast cancer has been reported. This is due, on the one hand, to the increase in the number of screening programs, which allow detection in early stages, and, on the other hand, to the aging of the population. The mortality rate has remained generally unchanged over the past 50 years despite improvements in treatment and early detection.
Factorii ce contribuie la apariţia cancerului mamar sunt: vârsta de 45…49 ani (premenopauza) şi un al doilea vârf între 60 şi 65 ani (postmenopauza), factorii hormonali, cancerul mamar este o boală hormono-dependentă. Femeile cu ovare nefuncţionale, care nu au primit niciodată tratament estrogenic de substituţie, nu fac cancer mamar. Mai multe dovezi indică faptul că hormonii joacă un rol cheie în promovarea bolii. Menarha precoce (înainte de 12 ani) şi menopauza tardivă (după 55 ani) cresc riscul de apariţie a cancerului mamar. Fiecare an de întârziere în apariţia primului ciclu, precum şi întârzierea în apariţia ciclurilor regulate duce la o creştere cu pană la 20% a riscului unui cancer mamar, iar numărul mare de sarcini duse până la termen şi alăptarea îndelungată la sân constituie factori de protecţie în apariţia cancerului mamar. Nuliparitatea, primiparitatea tardivă (după vârsta de 30 ani), precum şi avortul spontan sau provocat înaintea unei sarcini la termen cresc riscul de cancer mamar. Aportul extern de estrogeni cu progesteron folosit în contracepţie şi tratarea simptomelor de menopauză a dus la creşterea riscului de cancer mamar. De asemenea alte tulburări endocrine asociate tratamentului contraceptiv de tipul hiper sau hipotiroidia cresc relativ riscul de cancer mamar. Stările precanceroase ale glandei mamare, cum ar fi hiperplazia tipică şi atipică, metaplazia, displazia, distrofia (boala fibro-chistică) şi cancerul lobular în situ sunt leziuni care pot evolua către un cancer invaziv. De asemenea, tumorile benigne ale glandei mamare (fibroadenomul, adenomul juvenil), papilomatoza juvenilă, chisturile cu care au proliferări, tumoarea Phyllodes pot evolua în timp către un cancer mamar. Existenţa unei hiperplazii epiteliale intraductale atipice evoluează spre cancer mamar în circa 45%, în timp ce mastoza fibrochistică în circa 3% la paciente sub 20 ani, 7% la paciente sub 35 ani şi 30% la cele cu vârsta peste 45 ani. Factorii de mediu ca iradierea regiunii toracice mai ales înainte de 30 ani (bronhoscopiile repetate sau tratamentul pentru Boala Hodgkin), traumatismele mamare (mai ales cele mici şi repetate), expunerea sânilor la radiaţii ultraviolete pot influenta semnificativ apariţia cancerului mamar. De asemenea, o dietă alimentară bogată în proteine, grăsimi şi dulciuri, prin apariţia obezităţii creste riscul de cancer mamar. Dieta bogată în grăsimi reduce progesteronul plasmatic într-o fază de început, pentru ca ulterior depresia progesteronului să se asocieze cu creşterea ponderală. Ţesutul adipos în exces favorizează transformarea androgenilor suprarenali în estronă. Stresul, indiferent de natura lui, constituie un factor de risc atât pentru apariţia cancerului mamar, cât şi un factor de agravare a evoluţiei acestuia. Factorii genetici şi familiali, cum ar fi: factorul mamar de creştere derivat (mammary derived growth factor l) MI)GF I care a fost identificat în cancerele mamare şi care sugerează modificările autocrine sau paracrine care apar în celulele transformate. În celulele epiteliului mamar cu potenţial de transformare malignă se găsesc receptorii pentru MDGFI cât şi pentru alţi factori de creştere. Factors contributing to the occurrence of breast cancer are: age 45…49 years (premenopause) and a second peak between 60 and 65 years (postmenopause), hormonal factors, breast cancer is a hormone-dependent disease. Women with non-functional ovaries, who have never received estrogen replacement therapy, do not develop breast cancer. Several lines of evidence indicate that hormones play a key role in promoting the disease. Early menarche (before 12 years) and late menopause (after 55 years) increase the risk of breast cancer. Each year of delay in the appearance of the first cycle, as well as the delay in the appearance of regular cycles, leads to an increase of up to 20% in the risk of breast cancer, and the high number of pregnancies carried to term and long-term breastfeeding are protective factors in the occurrence of breast cancer. Nulliparity, late primiparity (after the age of 30), as well as spontaneous or induced abortion before a full-term pregnancy increase the risk of breast cancer. External intake of estrogens with progesterone used in contraception and treating menopausal symptoms has led to an increased risk of breast cancer. Also, other endocrine disorders associated with contraceptive treatment such as hyper or hypothyroidism relatively increase the risk of breast cancer. Precancerous conditions of the mammary gland, such as typical and atypical hyperplasia, metaplasia, dysplasia, dystrophy (fibrocystic disease) and lobular carcinoma in situ are lesions that can evolve into invasive cancer. Also, benign tumors of the mammary gland (fibroadenoma, juvenile adenoma), juvenile papillomatosis, cysts with which they have proliferations, Phyllodes tumor can evolve over time into breast cancer. The existence of atypical intraductal epithelial hyperplasia evolves into breast cancer in about 45%, while fibrocystic mastosis in about 3% in patients under 20 years of age, 7% in patients under 35 years of age and 30% in those over 45 years of age. Environmental factors such as irradiation of the thoracic region especially before 30 years of age (repeated bronchoscopies or treatment for Hodgkin's Disease), breast trauma (especially minor and repeated ones), exposure of the breasts to ultraviolet radiation can significantly influence the occurrence of breast cancer. Also, a diet rich in proteins, fats and sweets, through the occurrence of obesity, increases the risk of breast cancer. A diet rich in fat reduces plasma progesterone in an early phase, so that later progesterone depression is associated with weight gain. Excess adipose tissue favors the transformation of adrenal androgens into estrone. Stress, regardless of its nature, is a risk factor for both the occurrence of breast cancer and a factor aggravating its evolution. Genetic and familial factors, such as: mammary derived growth factor (MIGF I) which has been identified in breast cancers and which suggests autocrine or paracrine changes that occur in transformed cells. Receptors for MDGFI as well as other growth factors are found in breast epithelial cells with the potential for malignant transformation.
Pentru tratamentul cancerului glandei mamare în stadii precoce (T1-T2, No-N1) se utilizează metoda chirurgicală de tratament. Singura metodă eficientă este ablaţia completă (mastectomia) şi bilaterală a sânilor la femeile care au un risc crescut pentru cancer mamar. For the treatment of early stage breast cancer (T1-T2, No-N1), surgical treatment is used. The only effective method is complete and bilateral removal of the breasts (mastectomy) in women who are at high risk for breast cancer.
Procedeul este însă un exces greu de acceptat. Cu toate acestea există bolnave care solicită acest tip de intervenţie pentru a scăpa de obsesia cancerului. The procedure is, however, an excess that is difficult to accept. However, there are patients who request this type of intervention to get rid of the obsession with cancer.
Tratamentul chirurgical se prezintă prin: Mastectomia radicală (operaţia Halsted), Mastectomia radicală modificată ( tehnica Patey sau Madden), Chirurgia conservatoare mamară care presupune o sectorectomie cu obţinerea de margini de rezecţie histologic negativ şi limfadenectomie axilară, urmată de radioterapia externă la 2…3 săptămâni după intervenţia chirurgicală sau la sfârşitul chimioterapiei adjuvante postoperatorii, Chirurgia tumorii primare care este un tip de tratament ce poate fi efectuat numai în cazul tumorilor mici de până la 2…5 cm. Chiar şi în aceste cazuri, rezecându-se 2 cm peritumoral, într-un procent însemnat rămân focare neoplazice în glanda mamară. Surgical treatment is presented by: Radical mastectomy (Halsted operation), Modified radical mastectomy (Patey or Madden technique), Breast-conserving surgery which involves a sectorectomy with obtaining histologically negative resection margins and axillary lymphadenectomy, followed by external radiotherapy 2…3 weeks after surgery or at the end of postoperative adjuvant chemotherapy, Primary tumor surgery which is a type of treatment that can be performed only in the case of small tumors up to 2…5 cm. Even in these cases, resecting 2 cm peritumorally, in a significant percentage neoplastic foci remain in the mammary gland.
Pentru obţinerea unui rezultat estetic mai bun, incizia va fi radiară în cadranele inferioare şi arciformă în cele superioare. Dacă tumora este superficială este indicată extirparea tegumentelor supraiacente printr-o incizie eliptică. To obtain a better aesthetic result, the incision will be radial in the lower quadrants and arcuate in the upper ones. If the tumor is superficial, excision of the overlying skin through an elliptical incision is indicated.
Este cunoscută metoda de diminuare a complicaţiilor postradiante prin utilizarea preparatului Canefron H la pacienţii oncologici cu tumori ale organelor bazinului mic [1]. The method of reducing post-radiation complications by using the preparation Canephron H in oncological patients with tumors of the pelvic organs is known [1].
Dezavantajele acestei metode constau în posibilitatea apariţiei reacţiilor alergice la componenţii acestui produs şi utilizarea limitată a lui. The disadvantages of this method are the possibility of allergic reactions to the components of this product and its limited use.
În calitate de cea mai apropiată soluţie se cunoaşte metoda de diminuare a complicaţiilor postradiante care constă în aceea că se administrează intravenos o dată în zi îndată după masă, timp de 15 zile de la începutul cursului de radioterapie, 5 mL de soluţie de 5% de acid ascorbic şi peroral o capsulă (33000 UA) de retinol, o capsulă (0,2 g) de tocoferol şi un comprimat (0,2 g) de metiluracil. Totodată, concomitent se administrează ulei din seminţe de dovleac pe cale rectală sub formă de microclisme, în volum de 20 mL, cu o oră înainte de şedinţa de radioterapie. De asemenea uleiul se administrează peroral, câte o linguriţă (5 mL) de 2 ori pe zi, începând cu 2…3 zile înainte de iniţierea cursului de radioterapie, precum şi pe tot parcursul acesteia [2]. As the closest solution, the method of reducing postradiation complications is known, which consists in administering intravenously once a day immediately after a meal, for 15 days from the beginning of the radiotherapy course, 5 mL of a 5% ascorbic acid solution and peroral one capsule (33000 AU) of retinol, one capsule (0.2 g) of tocopherol and one tablet (0.2 g) of methyluracil. At the same time, pumpkin seed oil is administered rectally in the form of microenemas, in a volume of 20 mL, one hour before the radiotherapy session. The oil is also administered peroral, one teaspoon (5 mL) 2 times a day, starting 2…3 days before the initiation of the radiotherapy course, as well as throughout its duration [2].
Dezavantajele acestei metode constau în eficienţa scăzută şi în posibilitatea apariţiei complicaţiilor în urma chimioterapiei. The disadvantages of this method are its low efficiency and the possibility of complications following chemotherapy.
Problema pe care o rezolvă invenţia constă în extinderea arsenalului de metode utilizate pentru prevenirea complicaţiilor locale şi generale postradiante la pacientele operate cu cancer al glandei mamare. The problem solved by the invention consists in expanding the arsenal of methods used to prevent local and general post-radiation complications in patients operated on for breast cancer.
Conform invenţiei, metoda revendicată constă în aceea că se administrează 200 mL de un amestec pe bază de infuzie din rădăcini de păpădie şi partea vegetală de gălbenele, luate în raport de 1:1, şi nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, de două ori pe zi, cu 20 min înainte de masă, concomitent, o dată pe zi se administrează 20 mL de un amestec pe bază de ulei de amarant şi ricin, luate în raport de 1:1, şi nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, cu 20 min înainte de masă, cu 5 zile înainte de cura de radioterapie sau de chimioterapie, seria de tratament constituie 20…25 zile. According to the invention, the claimed method consists in administering 200 mL of a mixture based on an infusion of dandelion roots and the vegetable part of marigold, taken in a ratio of 1:1, and 4…10 nm nanodiamonds, in a concentration of 10-9…10-10 g/L, orally, twice a day, 20 min before a meal, simultaneously, once a day, 20 mL of a mixture based on amaranth and castor oil, taken in a ratio of 1:1, and 4…10 nm nanodiamonds, in a concentration of 10-9…10-10 g/L, orally, 20 min before a meal, 5 days before the radiotherapy or chemotherapy course, the treatment series is 20…25 days.
Rezultatul constă în diminuarea complicaţiilor locale şi generale după radioterapie şi/sau chimioterapie la bolnavele după tratament chirurgical al cancerului glandei mamare. Rezultatul obţinut se datorează combinării cantitative şi calitative a ingredientelor amestecului pe bază de infuzie din rădăcini de păpădie şi gălbenele şi a amestecului pe bază de ulei de amarant şi ricin ce conţin nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L. The result is the reduction of local and general complications after radiotherapy and/or chemotherapy in patients after surgical treatment of breast cancer. The result obtained is due to the quantitative and qualitative combination of the ingredients of the mixture based on infusion of dandelion roots and marigolds and the mixture based on amaranth and castor oil containing nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L.
O particularitate semnificativă a nanodiamantelor este că ele pătrund în membrana celulară şi pot precipita la suprafaţa sferică mai multe celule de substanţe biologic active, medicamente, polimere etc. Aceste caracteristici au stat la baza aplicării nanodiamantelor cu scop de dezintoxicare la pacienţii oncologici care au fost supuşi radio- şi chimioterapiei. A significant feature of nanodiamonds is that they penetrate the cell membrane and can precipitate on the spherical surface several cells of biologically active substances, drugs, polymers, etc. These characteristics formed the basis for the application of nanodiamonds for the purpose of detoxification in oncological patients who have undergone radio- and chemotherapy.
Praful de nanodiamante cu dimensiunile de 4…10 nm este obţinut conform brevetului RU 2465376 C1 2012.10.27 şi este accesibil pentru procurare în Federaţia Rusă. Nanodiamond powder with dimensions of 4…10 nm is obtained according to patent RU 2465376 C1 2012.10.27 and is available for purchase in the Russian Federation.
Infuzia din rădăcini de păpădie şi gălbenele se prepară în felul următor: masa vegetală, compusă din rădăcini de păpădie şi gălbenele, se fărâmiţează, la o parte de masă vegetală se adaugă 5 părţi de apă, se încălzeşte amestecul până la temperatura de 90°C, apoi se răceşte până la temperatura camerei timp de 24 ore şi se filtrează. The infusion of dandelion roots and marigolds is prepared as follows: the vegetable mass, composed of dandelion roots and marigolds, is crushed, 5 parts of water are added to one part of the vegetable mass, the mixture is heated to a temperature of 90°C, then cooled to room temperature for 24 hours and filtered.
Uleiul de amarant şi de ricin pot fi procurate în reţelele de farmacii din Republica Moldova. Amaranth and castor oil can be purchased in pharmacy chains in the Republic of Moldova.
Amestecul pe bază de infuzie din rădăcini de păpădie şi gălbenele se prepară în felul următor: într-un vas de 15 L se toarnă 10 L de infuzie din rădăcini de păpădie şi gălbenele şi se adaugă praf de nanodiamante până la concentraţia de 10-9…10-10 g/L, după care soluţia se malaxează timp de 2…3 min. The mixture based on dandelion root and marigold infusion is prepared as follows: in a 15 L vessel, pour 10 L of dandelion root and marigold infusion and add nanodiamond powder to a concentration of 10-9…10-10 g/L, after which the solution is mixed for 2…3 min.
Amestecul pe bază de ulei de amarant şi ricin se prepară în felul următor: într-un vas de 15 L se toarnă 5 L de ulei de amarant şi 5 L de ulei de ricin, se malaxează 2…3 min şi se adaugă praf de nanodiamante până la concentraţia de 10-9…10-10 g/L. The mixture based on amaranth and castor oil is prepared as follows: in a 15 L vessel, pour 5 L of amaranth oil and 5 L of castor oil, mix for 2…3 min and add nanodiamond powder to a concentration of 10-9…10-10 g/L.
Metoda revendicată se efectuează în felul următor: cu 5 zile înainte de cursul de radioterapie şi/sau chimioterapie se administrează un amestec în cantitate de 200 mL pe bază de infuzie din rădăcini de păpădie şi partea vegetală de gălbenele, care conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, de două ori pe zi, cu 20 min înainte de masă, totodată concomitent, o dată pe zi se administrează 20 mL de amestec pe bază de ulei de amarant şi ricin, luate în raport de 1:1, care conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, cu 20 min înainte de masă, seria de tratament constituie 20…25 zile. The claimed method is performed as follows: 5 days before the course of radiotherapy and/or chemotherapy, a mixture in an amount of 200 mL based on an infusion of dandelion roots and the vegetable part of marigold is administered, which contains nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L, orally, twice a day, 20 min before a meal, while simultaneously, once a day, 20 mL of a mixture based on amaranth and castor oil, taken in a ratio of 1:1, which contains nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L, orally, 20 min before a meal, the treatment series is 20…25 days.
Au fost efectuate cercetări asupra a 50 de femei care au suportat o intervenţie chirurgicală, ca rezultat al diagnosticării cancerului mamar şi care au suportat tratament postoperatoriu chimioterapeutic sau radioterapeutic, la fel a fost selectat un lot martor de 50 de femei, cărora li s-a administrat un tratament descris în soluţia cea mai apropiată cu scopul diminuării complicaţiilor chimioterapiei şi/sau radioterapiei. În calitate de criterii pentru aprecierea tratamentului revendicat au fost luate semnele cele mai frecvente ce apar în rezultatul administrării chimioterapiei ca: disbacterioza, gastrita, esofagita, reacţii alergice, anemia, polineuropatii, hepatite şi au fost apreciate conform criteriului stabilit de uniunea internaţională de combatere a cancerului care face parte din Organizaţia Internaţională a Sănătăţii: 0 - nu sunt manifestări, 1 - manifestări minime, 2 - manifestări moderate, 3 - manifestări esenţiale, 4 - manifestări ce pun în pericol viaţa pacientei. S-a stabilit că la utilizarea remediilor chimioterapeutice în doze minime timp de 15 zile şi a tratamentului conform celei mai apropiate soluţii s-au manifestat complicaţii ca disbacterioza, gastrita, esofagita, reacţii alergice, anemia, polineuropatii, hepatite apreciate prin gradul 3 de manifestări în 24% (12 paciente) din cazuri, iar conform soluţiei revendicate complicaţiile menţionate mai sus s-au manifestat numai la 8% (4 paciente) fiind apreciate prin gradul 2 de manifestări clinice postchimioterapeutice. La fel au fost apreciate aşa complicaţii ca alopecia şi arsurile. În cazul aplicării radioterapiei complicaţiile au fost apreciate conform gradului 2 de manifestări clinice la 14% ( 7 paciente), conform metodei revendicate la fel au fost apreciate manifestări clinice de gradul 2 la 12% (6 paciente). Şi în cazul aplicării chimioterapiei a fost selectat un lot de 50 paciente, cărora li s-a administrat un tratament conform metodei revendicate şi un lot martor de 50 de femei, cărora li s-a administrat un tratament conform celei mai apropiate soluţii. Research was conducted on 50 women who underwent surgery as a result of a breast cancer diagnosis and who underwent postoperative chemotherapeutic or radiotherapy treatment, as well as a control group of 50 women who were administered a treatment described in the closest solution with the aim of reducing the complications of chemotherapy and/or radiotherapy. As criteria for assessing the claimed treatment, the most frequent signs that appear as a result of chemotherapy administration were taken as: dysbacteriosis, gastritis, esophagitis, allergic reactions, anemia, polyneuropathies, hepatitis and were assessed according to the criteria established by the International Union for Cancer Control, which is part of the World Health Organization: 0 - no manifestations, 1 - minimal manifestations, 2 - moderate manifestations, 3 - essential manifestations, 4 - manifestations that endanger the patient's life. It was established that when using chemotherapeutic remedies in minimum doses for 15 days and treatment according to the closest solution, complications such as dysbacteriosis, gastritis, esophagitis, allergic reactions, anemia, polyneuropathies, hepatitis were manifested, assessed by grade 3 manifestations in 24% (12 patients) of cases, and according to the claimed solution, the complications mentioned above were manifested only in 8% (4 patients) being assessed by grade 2 post-chemotherapeutic clinical manifestations. Such complications as alopecia and burns were also assessed. In the case of radiotherapy, complications were assessed by grade 2 clinical manifestations in 14% (7 patients), according to the claimed method, clinical manifestations of grade 2 were also assessed in 12% (6 patients). And in the case of applying chemotherapy, a group of 50 patients was selected, who were administered a treatment according to the claimed method and a control group of 50 women, who were administered a treatment according to the closest solution.
Exemplu concret de realizare Concrete example of achievement
Pacientei B., 49 ani, cu diagnosticul de tumoare a glandei mamare stângi, i s-a efectuat o intervenţie chirurgicală cu sectorectomie cu obţinerea de margini de rezectie histologic negativ şi limfadenectomie axilară, apoi i s-a prescris chimioterapie. Cu 5 zile înainte de cursul de chimioterapie i s-a administrat un amestec în cantitate de 200 mL pe bază de infuzie din rădăcini de păpădie şi partea vegetală de gălbenele, care conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, de două ori pe zi, cu 20 min înainte de masă, totodată concomitent, o dată pe zi i s-a administrat 20 mL de amestec pe bază de ulei de amarant şi ricin, luate în raport de 1:1, care conţine nanodiamante de 4…10 nm, în concentraţie de 10-9…10-10 g/L, per os, cu 20 min înainte de masă, seria de tratament a constituit 20…25 zile. Complicaţiile specifice postchimioterapeutice nu s-au manifestat. Patient B., 49 years old, diagnosed with a tumor of the left mammary gland, underwent a surgical intervention with sectorectomy with histologically negative resection margins and axillary lymphadenectomy, then chemotherapy was prescribed. 5 days before the chemotherapy course, he was administered a mixture in an amount of 200 mL based on an infusion of dandelion roots and the vegetable part of marigold, which contains nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L, orally, twice a day, 20 min before a meal, while simultaneously, once a day, he was administered 20 mL of a mixture based on amaranth and castor oil, taken in a ratio of 1:1, which contains nanodiamonds of 4…10 nm, in a concentration of 10-9…10-10 g/L, orally, 20 min before a meal, the treatment series was 20…25 days. Specific post-chemotherapy complications did not occur.
1. Каприн А.Д., Семин А.В., Костин А.А. Эффективность препарата "Канефрон Н" у онкологически больных получающих лучевую терапию на органы малого таза. Человек и лекарство, №5, том 15, 2007 1. Kaprin A.D., Semin A.V., Kostin A.A. The effectiveness of the preparation "Kanefron H" in oncological patients receiving radiation therapy on pelvic organs. Man and medicine, №5, volume 15, 2007
2. MD 482 Z 2012.09.30 2. MD 482 Z 2012.09.30
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140054A MD871Z (en) | 2014-04-18 | 2014-04-18 | Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140054A MD871Z (en) | 2014-04-18 | 2014-04-18 | Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD871Y MD871Y (en) | 2015-01-31 |
| MD871Z true MD871Z (en) | 2015-09-30 |
Family
ID=52440959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20140054A MD871Z (en) | 2014-04-18 | 2014-04-18 | Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD871Z (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| RU2197977C2 (en) * | 2001-04-17 | 2003-02-10 | Дмитриенко Николай Васильевич | Pumpkin seed oil eliciting anti-inflammatory, antiulcerous and hepatoprotective effect and method of its preparing |
| EA201001000A1 (en) * | 2010-04-19 | 2011-10-31 | Алмагуль Тулеуовна Маншарипова | ANTIOXIDANT MEANS OIL BALSAM "JEWELAX" |
-
2014
- 2014-04-18 MD MDS20140054A patent/MD871Z/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD482F1 (en) * | 1995-12-29 | 1996-10-31 | Svetskii & Co Fa | Continuous acted mixer |
| RU2197977C2 (en) * | 2001-04-17 | 2003-02-10 | Дмитриенко Николай Васильевич | Pumpkin seed oil eliciting anti-inflammatory, antiulcerous and hepatoprotective effect and method of its preparing |
| EA201001000A1 (en) * | 2010-04-19 | 2011-10-31 | Алмагуль Тулеуовна Маншарипова | ANTIOXIDANT MEANS OIL BALSAM "JEWELAX" |
Non-Patent Citations (2)
| Title |
|---|
| Каприн А.Д., Семин А.В., Костин А.А. Эффективность препарата "Канефрон Н" у онкологически больных получающих лучевую терапию на органы малого таза. Человек и лекарство, №5, том 15, 2007 * |
| Ролик И.С. Биологические препараты в реабилитации больных раком: руководство для врачей. Москва, Арнебия, 2000 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD871Y (en) | 2015-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Azeez et al. | New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling | |
| Russo et al. | Toward a physiological approach to breast cancer prevention. | |
| Berclaz et al. | Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast | |
| ES2808076T3 (en) | Regulator of hormonal secretion, composition that contains it and procedure to control hormonal secretion through its use | |
| Hsu et al. | The effects of isoliquiritigenin on endometriosis in vivo and in vitro study | |
| Muñoz et al. | Ovarian stimulation in patients with breast cancer | |
| Jordan et al. | Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer | |
| Xiao et al. | Differential effects of oestradiol and progesterone on proliferation and morphology of cultured bovine uterine epithelial and stromal cells | |
| US11110101B2 (en) | Prostate function support formula | |
| MD871Z (en) | Method for prophylaxis of radiotherapy or chemotherapy complications in patients with breast cancer | |
| M. Chinnappan et al. | Effect of herbal extract Eurycoma longifolia (Physta®) on female reproductive hormones and bone biochemical markers: an ovariectomised rat model study | |
| Wang et al. | Qingchang mixture prevents the intestinal ischemia-reperfusion injury through tlr4/nf-kb pathway | |
| Septiani et al. | Role of the red fruit (Pandanus conoideus Lam) ethyl acetate fraction on the induction of apoptosis vs. downregulation of survival signaling pathways in cervical cancer cells | |
| CN104587140B (en) | Black false hellebore estrogen receptor antagon sample new role | |
| de Carvalho et al. | First pregnancy and live birth from ex vivo-retrieved metaphase II oocytes from a woman with bilateral ovarian carcinoma: a case report | |
| Almalki | The Effects of Wild Yam Root (Dioscorea villosa) Extract in Human Triple Negative MDA-MB-231 Breast Cancer Cells | |
| Faisal et al. | Histopathological effects of Eurycoma longifolia Jack extract (Tongkat Ali) on the prostate of rats | |
| Sharma et al. | Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer | |
| CN115944644B (en) | Composition with efficacy of improving hypoovarianism and application thereof | |
| Vatavu et al. | BREAST ABNORMALITIES AND CONGENITAL ANOMALIES. | |
| WO2019024249A1 (en) | Placental extract biological gel preparation for treating premature ovarian failure, and method of preparing same | |
| Lang et al. | Kuntai Capsule Improves Ovarian Function in Rats with Premature Ovarian Failure After Transplantation of Cryopreserved Ovarian Tissue by Regulating Sex Hormones and Apoptosis | |
| WILLIAMSON et al. | Bilateral gonadoblastoma with dysgerminoma: A case report | |
| Jayaraman et al. | Black Horehound (Ballota nigra Linn) Induces Apoptosis in Prostate Cancer Cells (PC-3) Through Intrinsic Signalling Cascade | |
| Hanikezi et al. | Impacts of isoliquiritigenin on proliferation and apoptosis of human cervical cancer cells. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |